- Home
- GRNT vs AUPH Comparison
GRNT vs AUPH Comparison
Compare GRNT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRNT | AUPH |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.8M | 1.6B |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GRNT | AUPH |
|---|---|---|
| Price | $5.18 | $13.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 703.6K | ★ 903.8K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 8.59% | N/A |
| EPS Growth | 28.57 | ★ 5075.00 |
| EPS | 0.18 | ★ 2.07 |
| Revenue | ★ $450,306,000.00 | $283,055,000.00 |
| Revenue This Year | $22.96 | $17.35 |
| Revenue Next Year | $5.78 | $15.66 |
| P/E Ratio | $28.44 | ★ $6.95 |
| Revenue Growth | 18.49 | ★ 20.38 |
| 52 Week Low | $4.18 | $6.83 |
| 52 Week High | $6.59 | $16.54 |
Technical Indicators
Market Signals| Indicator | GRNT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 41.68 |
| Support Level | $4.83 | $13.52 |
| Resistance Level | $5.45 | $15.23 |
| Average True Range (ATR) | 0.22 | 0.57 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 64.19 | 24.42 |
Price Performance
Historical ComparisonAbout GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.